The Scoop
Roche plans to acquire SAGA Diagnostics for up to $595M by Q3 2026. SAGA's Pathlight MRD platform will integrate into Foundation Medicine, expanding cancer surveillance globally.
The Context
SAGA Diagnostics, based in Sweden and North Carolina, specializes in ultra-sensitive cancer monitoring through blood-based testing. The acquisition by Roche, a global pharma giant, highlights the growing demand for precision oncology and MRD technologies. Roche's move builds upon its existing diagnostics portfolio, strengthening its position against competitors like Guardant Health.